Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea

Main Article Content

Linda Stein Gold
James Q Del Rosso
Leon Kircik
Neal D Bhatia
Deirdre Hooper
Walter Nahm
Iain Stuart

Keywords

Rosacea, Minocycline, Topical, Safety, Efficacy

Abstract

Abstract Not Available.

References

1. Li WQ, Cho E, Khalili H, et al. Rosacea, use of tetracycline, and risk of incident
inflammatory bowel disease in women. Clin Gastroenterol Hepatol. 2016;14(2):220-225.

2. Taieb A, Stein Gold L, Feldman SR, et al. Cost-effectiveness of ivermectin 1% cream
in adults with papulopustular rosacea in the United States. J Manag Care Spec Pharm.
2016;22(6):654-665.

3. Rainer BM, Kang S, Chien AL. Rosacea: epidemiology, pathogenesis, and treatment.
Dermatoendocrinol. 2017;9(1):e131574.

4. Goldgar C, Keahey DJ, Houchins J. Treatment options for acne rosacea. Am Fam
Physician. 2009;80(5):461-468.

5. Oge LK, Munchie HL, Phillips-Savoy AR. Rosacea: diagnosis and treatment. Am Fam
Physician. 2015;92(3):187-196.

6. Fiscus V, Hankinson A, Alweis R. Minocycline-induced hyperpigmentation. J Community
Hosp. 2014;4:24063.

7. Valentín S, Morales A, Sánchez JL, Rivera A. Safety and efficacy of doxycycline in the
treatment of rosacea. Clin Cosmet Investig Dermatol. 2009;2:129-140.

8. Stein Gold L, Del Rosso JQ, Kircik L, et al. Minocycline 1.5% foam for the topical treatment of moderate-to-severe papulopustular rosacea: Results